Research
Filter News
Found 146,432 articles
-
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
12/21/2023
JCR Pharmaceuticals Co., Ltd. announced today that Takeda Pharmaceutical Co., Ltd. (“Takeda”) decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo ® Technology.
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
12/21/2023
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB.
-
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
12/21/2023
Natera, Inc. today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA).
-
Fauna Bio Announces Strategic Collaboration with Lilly to Discover Novel Obesity Targets Using Convergence™ AI Platform
12/21/2023
Fauna Bio today announced a multi-year agreement with Eli Lilly and Company to apply Fauna's Convergence™ artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity.
-
NS-089/NCNP-02 Receives Orphan Drug Designation from the European Commission for the Treatment of Duchenne Muscular Dystrophy
12/21/2023
NS Pharma, Inc. has granted orphan drug designation for NS-089/NCNP-02, which is being developed for the treatment of Duchenne muscular dystrophy (Duchenne).
-
ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics
12/21/2023
ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics.
-
Pluristyx Announces Major New Funding Round to Bolster Expansion Plans
12/21/2023
Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners.
-
Lyndra Therapeutics Raises $101 Million in Series E Funding
12/21/2023
Lyndra Therapeutics today announced the closing of a $101 million Series E financing round.
-
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
12/21/2023
DMK Pharmaceuticals Corporation announces that it has regained the full rights to commercialize ZIMHI ® (naloxone) after the termination of an exclusive commercialization and distribution with US WorldMeds, LLC.
-
Thermo Fisher Scientific’s PPD Clinical Research Business Selected by BARDA to Support Phase II Platform Clinical Trial to Treat Acute Respiratory Distress Syndrome (ARDS)
12/21/2023
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).
-
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
12/21/2023
NightHawk Biosciences today announced its Scorpius BioManufacturing subsidiary (“Scorpius”) completed a demonstration run in the Company’s process development lab for a microbial vaccine program developed by a top-tier research university that is NIH and DTRA (Defense Threat Reduction Agency) funded.
-
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
12/21/2023
Apnimed, Inc. today announced the first patient dosed in its SynAIRgy Phase 3 study designed to examine the efficacy and safety of AD109 (aroxybutynin/atomoxetine) compared to placebo at six-months.
-
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
12/21/2023
IO Biotech announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA.
-
TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma
12/21/2023
TransThera today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420).
-
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
12/21/2023
RenovoRx, Inc today announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial.
-
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
12/21/2023
Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on SON-1210 in Frontiers in Immunology.
-
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/21/2023
ITM Isotope Technologies Munich SE today announced that CEO, Steffen Schuster and CFO, Dr. Klaus Maleck will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
-
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
12/20/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the launch of the Myriad Collaborative Research Registry™.
-
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
12/20/2023
Daré Bioscience, Inc., a leader in women’s health innovation, announced positive topline results from the Phase 1 study evaluating the pharmacokinetics, safety, and exploratory efficacy of DARE-PDM1.
-
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
12/20/2023
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, reported new data on Namodenoson’s anti-obesity mechanism of action.